- Home
- XNCR vs AUTL Comparison
XNCR vs AUTL Comparison
Compare XNCR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- AUTL
- Stock Information
- Founded
- XNCR 1997
- AUTL 2014
- Country
- XNCR United States
- AUTL United Kingdom
- Employees
- XNCR N/A
- AUTL N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XNCR Health Care
- AUTL Health Care
- Exchange
- XNCR Nasdaq
- AUTL Nasdaq
- Market Cap
- XNCR 547.8M
- AUTL 625.4M
- IPO Year
- XNCR 2013
- AUTL 2018
- Fundamental
- Price
- XNCR $8.60
- AUTL $1.38
- Analyst Decision
- XNCR Buy
- AUTL Strong Buy
- Analyst Count
- XNCR 10
- AUTL 5
- Target Price
- XNCR $23.33
- AUTL $9.12
- AVG Volume (30 Days)
- XNCR 700.0K
- AUTL 4.6M
- Earning Date
- XNCR 11-05-2025
- AUTL 11-11-2025
- Dividend Yield
- XNCR N/A
- AUTL N/A
- EPS Growth
- XNCR N/A
- AUTL N/A
- EPS
- XNCR N/A
- AUTL N/A
- Revenue
- XNCR $146,929,000.00
- AUTL $29,934,000.00
- Revenue This Year
- XNCR $22.06
- AUTL $634.25
- Revenue Next Year
- XNCR N/A
- AUTL $93.16
- P/E Ratio
- XNCR N/A
- AUTL N/A
- Revenue Growth
- XNCR N/A
- AUTL 185.17
- 52 Week Low
- XNCR $6.92
- AUTL $1.11
- 52 Week High
- XNCR $27.24
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- XNCR 57.89
- AUTL 28.28
- Support Level
- XNCR $8.25
- AUTL $1.34
- Resistance Level
- XNCR $8.73
- AUTL $1.46
- Average True Range (ATR)
- XNCR 0.38
- AUTL 0.10
- MACD
- XNCR 0.07
- AUTL 0.01
- Stochastic Oscillator
- XNCR 78.76
- AUTL 11.11
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.